Literature DB >> 17560621

Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens.

Nina R Derby1, Sean Gray, Elizabeth Wayner, Dwayne Campogan, Giorgos Vlahogiannis, Zane Kraft, Susan W Barnett, Indresh K Srivastava, Leonidas Stamatatos.   

Abstract

Eleven anti-HIV Env monoclonal antibodies (MAbs) were isolated from mice immunized with soluble Env proteins derived from the clade B Env, SF162, or DeltaV2 (a derivative of SF162 lacking the V2 loop). All six anti-gp120 MAbs studied, neutralized SF162 and their activities were dependent by the glycosylation patterns of the V1, V2 or V3 loops. Only one anti-gp120 MAb (an anti-V3 MAb) displayed cross-neutralizing activity, which was influenced by the type of V1 loop present on the target heterologous viruses. None of the five anti-gp41 MAbs studied displayed anti-SF162 neutralizing activity. Our studies indicate that the current limitation of soluble HIV Env gp140 immunogens to elicit robust cross-reactive neutralizing antibody responses is not only due to the elicitation of high titers of homologous antibodies but also due to the elicitation of antibodies whose epitopes are naturally occluded, or not present, on the virion-associated Env.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17560621      PMCID: PMC2048818          DOI: 10.1016/j.virol.2007.05.020

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  46 in total

1.  Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.

Authors:  X Yang; R Wyatt; J Sodroski
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

2.  Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates.

Authors:  L Stamatatos; M Lim; C Cheng-Mayer
Journal:  AIDS Res Hum Retroviruses       Date:  2000-07-01       Impact factor: 2.205

3.  The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.

Authors:  S W Barnett; S Lu; I Srivastava; S Cherpelis; A Gettie; J Blanchard; S Wang; I Mboudjeka; L Leung; Y Lian; A Fong; C Buckner; A Ly; S Hilt; J Ulmer; C T Wild; J R Mascola; L Stamatatos
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  Viral evolution in macaques coinfected with CCR5- and CXCR4-tropic SHIVs in the presence or absence of vaccine-elicited anti-CCR5 SHIV neutralizing antibodies.

Authors:  Brian Burke; Nina R Derby; Zane Kraft; Cheryl J Saunders; Chuanbin Dai; Nicholas Llewellyn; Irina Zharkikh; Lucia Vojtech; Tuofu Zhu; Indresh K Srivastava; Susan W Barnett; Leonidas Stamatatos
Journal:  Virology       Date:  2006-08-22       Impact factor: 3.616

5.  Human immunodeficiency virus type 1 envelope glycoprotein oligomerization requires the gp41 amphipathic alpha-helical/leucine zipper-like sequence.

Authors:  P Poumbourios; K A Wilson; R J Center; W El Ahmar; B E Kemp
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

6.  Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1.

Authors:  C P Krachmarov; W J Honnen; S C Kayman; M K Gorny; S Zolla-Pazner; Abraham Pinter
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

7.  Collection of phage-peptide probes for HIV-1 immunodominant loop-epitope.

Authors:  Yadira Palacios-Rodríguez; Tatiana Gazarian; Merrill Rowley; Abraham Majluf-Cruz; Karlen Gazarian
Journal:  J Microbiol Methods       Date:  2006-10-12       Impact factor: 2.363

8.  Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.

Authors:  P L Earl; W Sugiura; D C Montefiori; C C Broder; S A Lee; C Wild; J Lifson; B Moss
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

9.  V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies.

Authors:  A Ly; L Stamatatos
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

10.  The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors.

Authors:  S E Malenbaum; D Yang; L Cavacini; M Posner; J Robinson; C Cheng-Mayer
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

View more
  17 in total

1.  Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses.

Authors:  Xueling Wu; Anna Sambor; Martha C Nason; Zhi-Yong Yang; Lan Wu; Susan Zolla-Pazner; Gary J Nabel; John R Mascola
Journal:  Virology       Date:  2008-09-18       Impact factor: 3.616

2.  Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection.

Authors:  Anne-Sophie Dugast; Leonidas Stamatatos; Andrew Tonelli; Todd J Suscovich; Anna F Licht; Iliyana Mikell; Margaret E Ackerman; Hendrik Streeck; P J Klasse; John P Moore; Galit Alter
Journal:  Eur J Immunol       Date:  2014-08-11       Impact factor: 5.532

3.  Neutralizing capacity of monoclonal antibodies that recognize peptide sequences underlying the carbohydrates on gp41 of simian immunodeficiency virus.

Authors:  José M Martinez-Navio; Ronald C Desrosiers
Journal:  J Virol       Date:  2012-09-19       Impact factor: 5.103

4.  Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs.

Authors:  Joseph P Nkolola; Hanqin Peng; Ethan C Settembre; Michael Freeman; Lauren E Grandpre; Colleen Devoy; Diana M Lynch; Annalena La Porte; Nathaniel L Simmons; Ritu Bradley; David C Montefiori; Michael S Seaman; Bing Chen; Dan H Barouch
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

5.  Introduction of exogenous epitopes in the variable regions of the human immunodeficiency virus type 1 envelope glycoprotein: effect on viral infectivity and the neutralization phenotype.

Authors:  Aaron Wallace; Leonidas Stamatatos
Journal:  J Virol       Date:  2009-06-03       Impact factor: 5.103

6.  The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen.

Authors:  Lance K Ching; Giorgos Vlachogiannis; Katherine A Bosch; Leonidas Stamatatos
Journal:  J Virol       Date:  2007-11-14       Impact factor: 5.103

7.  Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination.

Authors:  Michael Vaine; Shixia Wang; Emma T Crooks; Pengfei Jiang; David C Montefiori; James Binley; Shan Lu
Journal:  J Virol       Date:  2008-05-21       Impact factor: 5.103

8.  Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits.

Authors:  Delphine C Malherbe; Franco Pissani; D Noah Sather; Biwei Guo; Shilpi Pandey; William F Sutton; Andrew B Stuart; Harlan Robins; Byung Park; Shelly J Krebs; Jason T Schuman; Spyros Kalams; Ann J Hessell; Nancy L Haigwood
Journal:  J Virol       Date:  2014-09-10       Impact factor: 5.103

9.  Chemically modified peptides based on the membrane-proximal external region of the HIV-1 envelope induce high-titer, epitope-specific nonneutralizing antibodies in rabbits.

Authors:  Vincent J Venditto; Lindsay Wieczorek; Sebastian Molnar; Fernando Teque; Gary Landucci; Douglas S Watson; Donald Forthal; Victoria R Polonis; Jay A Levy; Francis C Szoka
Journal:  Clin Vaccine Immunol       Date:  2014-05-28

10.  Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins.

Authors:  Feng Gao; Richard M Scearce; S Munir Alam; Bhavna Hora; Shimao Xia; Julie E Hohm; Robert J Parks; Damon F Ogburn; Georgia D Tomaras; Emily Park; Woodrow E Lomas; Vernon C Maino; Susan A Fiscus; Myron S Cohen; M Anthony Moody; Beatrice H Hahn; Bette T Korber; Hua-Xin Liao; Barton F Haynes
Journal:  Virology       Date:  2009-09-09       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.